Lyell Immunopharma, Inc. Logo

Lyell Immunopharma, Inc.

Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.

LYEL | US

Overview

Corporate Details

ISIN(s):
US55083R1041
LEI:
Country:
United States of America
Address:
201 HASKINS WAY, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company focused on developing transformative Chimeric Antigen Receptor (CAR) T-cell therapies for patients with solid tumors and hematologic malignancies. The company's scientific platform is designed to overcome key barriers to successful cell therapy, such as T-cell exhaustion, to generate more durable and effective treatments. Lyell is advancing a pipeline of next-generation product candidates targeting cancers with significant unmet medical need. A lead candidate, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CD19/CD20 therapy being evaluated in clinical trials for aggressive large B-cell lymphoma.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lyell Immunopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lyell Immunopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lyell Immunopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Mind Medicine (MindMed) Inc. Logo
Developing psychedelic-inspired medicines and novel therapies for brain health disorders.
United States of America
MNMD
Mineralys Therapeutics, Inc. Logo
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
United States of America
MLYS
MiNK Therapeutics, Inc. Logo
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
United States of America
INKT
MIRA PHARMACEUTICALS, INC. Logo
Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.
United States of America
MIRA
Mirum Pharmaceuticals, Inc. Logo
Develops and commercializes therapies for rare, debilitating liver diseases in children and adults.
United States of America
MIRM
Mithra Pharmaceuticals S.A. Logo
Biotech firm developing pharma for women's health: contraception, fertility, and menopause.
Belgium
MITRA
MIZUHO MEDY CO.,LTD. Logo
Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.
Japan
4595
MOA Life Plus Co. Ltd. Logo
Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.
South Korea
142760
Moberg Pharma Logo
Develops & commercializes a leading topical treatment for nail fungus for European markets.
Sweden
MOB
Mochida Pharmaceutical Co.,Ltd. Logo
An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.
Japan
4534

Talk to a Data Expert

Have a question? We'll get back to you promptly.